Should I Buy SER? SER 2026 Analysis

Should You Buy Serina Therapeutics Inc (SER) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

3.540

1 Day change

30.15%

52 Week Range

7.920

Analysis Updated At

2026/01/26

Serina Therapeutics Inc (SER) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's financial performance is extremely poor, with significant revenue, net income, and EPS declines. There are no positive trading trends, no recent news, and no analyst ratings or positive catalysts to support a buy decision. Additionally, technical indicators do not suggest a strong entry point, and Intellectia Proprietary Trading Signals show no buy signals today. The stock's trend indicates a higher likelihood of decline in the short to medium term.

Technical Analysis

The MACD is positive but contracting, RSI is neutral at 58.937, and moving averages are converging, indicating no clear trend. Key support and resistance levels suggest limited upside potential (R1: 3.097, R2: 3.328) with significant downside risk (S1: 2.348, S2: 2.117). Overall, technical indicators do not strongly support a buy decision.

Options Data

Positive Catalysts

NULL identified. No recent news, no significant trading trends, and no positive financial performance.

Neutral/Negative Catalysts

The company's financials for Q3 2025 show a 100% revenue drop, a net income decline of -425.18% YoY, and an EPS drop of -438.46% YoY. Additionally, the stock trend analysis suggests a higher probability of short-term and medium-term declines.

Financial Performance

In Q3 2025, revenue dropped to 0 (-100% YoY), net income dropped to -$4,585,000 (-425.18% YoY), and EPS dropped to -0.44 (-438.46% YoY). Gross margin remained at 100%, but this is not indicative of strong performance given the lack of revenue.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst ratings or price target changes available.

1 Analyst Rating

Wall Street analysts forecast SER stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SER is 11 USD with a low forecast of 11 USD and a high forecast of 11 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 2.720

Low

Averages

High

Current: 2.720

Low

Averages

High

H.C. Wainwright

Buy

initiated

$15

AI Analysis

2025-07-14

Reason

H.C. Wainwright

Price Target

$15

AI Analysis

2025-07-14

initiated

Buy

Reason

H.C. Wainwright initiated coverage of Serina Therapeutics with a Buy rating and $15 price target. The firm says Serina is an emerging biopharmaceutical company focused on developing next-generation versions of existing active pharmaceutical ingredients.

Jones Trading

Justin Walsh

Strong Buy

Initiates

$11

2025-03-11

Reason

Jones Trading

Justin Walsh

Price Target

$11

2025-03-11

Initiates

Strong Buy

Reason

JonesResearch analyst Justin Walsh initiated coverage of Serina Therapeutics (SER) with a Buy rating and $11 price target. Serina is a drug delivery and soon-to-be clinical stage biotech company that went public via a reverse merger with AgeX Therapeutics in March of last year whose lead asset, SER-252, is being developed for the management of motor fluctuations and dyskinesia in patients with advanced Parkinson's Disease. The firm has "high confidence" that SER-252 will at least match the efficacy observed with other apomorphine delivery approaches, such as Supernus' (SUPN) recently approved Onapgo, while delivering improved tolerability and convenience, the analyst tells investors.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for SER

Unlock Now

SER Should I Buy

SER Should I Buy

Should You Buy Serina Therapeutics Inc (SER) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch